In the context of LC, mutations in the EGFR, ALK, ROS-1, BRAF, NTRK, MET, RET, HER2, and KRAS genes are predictive markers of sensitivity to the corresponding tyrosine kinase inhibitors (TKIs). This evidence concerns the gene KRAS and laryngotracheoesophageal cleft.